Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ambrisentan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRB known ✓ | P24530 | 16/20 | 1.00 |
| ▸ | EDNRA known ✓ | P25101 | 16/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | KCNE1 | P15382 | 1/20 | 1.00 |
| ▸ | KCNQ1 | P51787 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | IL36G | Q9NZH8 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ambrisentan SCHEMBL3023434 | 1.00 | EDNRB (1.00) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| Ambrisentan SCHEMBL138157 | 1.00 | EDNRB (1.00) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| Ambrisentan SCHEMBL20769813 | 1.00 | EDNRB (1.00) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| SCHEMBL7934042 | 0.91 | EDNRB (1.00) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| SCHEMBL2352546 | 0.90 | EDNRB (0.81) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| SCHEMBL2356501 | 0.90 | EDNRB (0.81) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| SCHEMBL3023829 | 0.89 | EDNRB (0.83) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| SCHEMBL3023827 | 0.89 | EDNRB (0.83) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| SCHEMBL3028683 | 0.89 | EDNRB (0.80) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| SCHEMBL7933350 | 0.89 | EDNRB (1.00) | EDNRBEDNRANR1I2KCNE1KCNQ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 8032 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3810091-B1 | COMPOSITIONS FOR TREATING PULMONARY HYPERTENSION | ABRAXIS BIOSCIENCE LLC (US) | 2026-05-20 | — | — | EP | claimed |
| EP-4736841-A1 | A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT | IQ medical GmbH (DE) | 2026-05-06 | — | — | EP | claimed |
| US-12577300-B2 | Neutralizing antibodies to human endothelin | Father Flanagan's Boys' Home Business (US) | 2026-03-17 | — | — | US | claimed |
| EP-3532063-B1 | COMBINATION THERAPY FOR TREATING PULMONARY HYPERTENSION | PULMOKINE INC (US) | 2026-03-04 | — | — | EP | claimed |
| EP-4696689-A1 | SALT FORM AND CRYSTAL FORM OF CHIRAL HETEROCYCLIC COMPOUND HAVING HEDGEHOG PATHWAY ANTAGONIST ACTIVITY | Suzhou Kintor Pharmaceuticals, Inc. (CN) | 2026-02-18 | — | — | EP | claimed |
| EP-4691470-A1 | USE OF HETEROCYCLIC COMPOUND IN TREATMENT OF INTERSTITIAL PNEUMONIA | SUZHOU KINTOR PHARMACEUTICALS, INC (CN) | 2026-02-11 | — | — | EP | claimed |
| EP-4355915-B1 | METHOD FOR NASH RISK ASSESSMENT IN PATIENTS HAVING A METABOLIC DISORDER | GENFIT (FR) | 2026-02-04 | — | — | EP | claimed |
| EP-4684777-A1 | A FIXED-DOSE PHARMACEUTICAL COMPOSITION COMPRISING (2S)-2-[(4,6-DIMETHYLPYRIMIDIN-2-YL)OXY]-3-METHOXY-3,3-DIPHENYLPROPANOIC ACID AND (6R,12AR)-6-(1,3-BENZODIOXOL-5-YL)-2-METHYL-2,3,6,7,12,12A-HEXAHYDROPYRAZINO{1',2:1,6]PYRIDO[3,4-B]INDOLE-1,4-DIONE | Adalvo Limited (MT) | 2026-01-28 | — | — | EP | claimed |
| US-12527839-B2 | Treatments for systemic sclerosis | ACCELERON PHARMA INC. (US) | 2026-01-20 | — | — | US | claimed |
| US-12521379-B2 | Use of FK506 for the treatment of pulmonary arterial hypertension | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2026-01-13 | — | — | US | claimed |
| EP-1553950-A1 | THERAPEUTIC TREATMENT | Astrazeneca AB (SE) | 2005-07-20 | — | — | EP | claimed |
| EP-1551395-A1 | 5-HT 1B/1D RECEPTOR AGONISTS FOR THE TREATMENT OF HEADACHE RESULTING FROM ADMINISTERING AN ENDOTHELIN RECEPTOR ANTAGONIST | AstraZeneca AB (SE) | 2005-07-13 | — | — | EP | claimed |
| US-20050119330-A1 | Use of antiproliferative agents in the treatment and prevention of pulmonary proliferative vascular diseases | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2005-06-02 | — | — | US | claimed |
| US-20050101608-A1 | Iloprost in combination therapies for the treatment of pulmonary arterial hypertension | COTHERIX, INC. | 2005-05-12 | — | — | US | claimed |
| WO-2005030187-A2 | ILOPROST IN COMBINATION THERAPIES FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | COTHERIX, INC. (US) | 2005-04-07 | — | — | WO | claimed |
| WO-2004082637-A2 | COMBINATION OF AN ALDOSTERONE RECEPTOR ANTAGONIST AND AN ENDOTHELIN RECEPTOR ANTAGONIST AND/OR ENDOTHELIN CONVERTING ENZYME INHIBITOR | PHARMACIA CORPORATION (US) | 2004-09-30 | — | — | WO | claimed |
| US-20040186083-A1 | Combination of an aldosterone receptor antagonist and an endothelin receptor antagonist and/or endothelin converting enzyme inhibitor | PHARMACIA CORPORATION | 2004-09-23 | — | — | US | claimed |
| US-20040105819-A1 | comprise respiratory drug condensation aerosol particles; selected from the group consisting of beta -adrenergics, methylxanthines, anticholinergics, corticosteroids, mediator-release inhibitors, anti-leukotriene drugs, asthma inhibitors etc | ALEXZA MOLECULAR DELIVERY CORPORATION (US) | 2004-06-03 | — | — | US | claimed |
| WO-2004035057-A1 | THERAPEUTIC TREATMENT | ASTRAZENECA AB (SE) | 2004-04-29 | — | — | WO | claimed |
| WO-2004032922-A1 | 5-HT 1B/1D RECEPTOR AGONISTS FOR THE TREATMENT OF HEADACHE RESULTING FROM ADMINISTERING AN ENDOTHELIN RECEPTOR ANTAGONIST | ASTRAZENECA AB (SE) | 2004-04-22 | — | — | WO | claimed |